Our Team

Scientist in laboratory looking through a microscope

Working together to prevent blindness

Odylia Therapeutics is a 501(c)(3) corporation combining the expertise and experience of our founders, board members, and partner organizations to fill a unique void in moving ultra-rare inherited retinal diseases from science to humans. Our organization focuses on those diseases that would typically have limited commercial appeal and would be neglected, even though the science is available to make significant progress.

Board of Directors

Luk Vandenberghe, PhD
Associate Professor, Harvard Medical School
Director, Grousbeck Gene Therapy Center
Massachusetts Eye and Ear

Scott Dorfman, CEO and co-founder of Odylia Therapeutics

Scott Dorfman, BBA
CEO, Odylia Therapeutics

Matthew Pletcher, PhD
RDH12 Fund for Sight

Emil Kakkis, MD, PhD
President and Founder
Ultragenyx Pharmaceutical Inc

Advisory Board

Eric A. Pierce, M.D., Ph.D., Director of the Inherited Retinal Disorders Service at Massachusetts Eye and Ear

Eric Pierce, MD, PhD
Director, Ocular Genomics Institute
Harvard Medical School
Director, Inherited Retinal Disorders Services
Massachusetts Eye and Ear

Joy Cavagnaro, PhD
President, Access Bio

Jean Bennett, MD, PhD
Professor, Perelman School of Medicine
University of Pennsylvania

Alberto Auricchio, Ph.D., Associate Professor of Medical Genetics at Federico II University Napoli and Principal Investigator, TIGEM

Alberto Auricchio, PhD
Associate Professor of Medical Genetics
“Federico II” University Napoli
Principal Investigator, TIGEM

Alan Spiro, BA, PhD, JD
Partner, ExSight Ventures

Gregory Robinson, PhD
Chief Scientific Officer, Akouos

Founding Members

Luk Vandenberghe, PhD
Associate Professor, Harvard Medical School
Director, Grousbeck Gene Therapy Center
Massachusetts Eye and Ear

Eric Pierce, MD, PhD
Director, Ocular Genomics Institute
Harvard Medical School
Director, Inherited Retinal Disorders Services
Massachusetts Eye and Ear